ABSTRACT
INTRODUCTION: Previously we reported a 2-month clinical trial of moxifloxacin therapy in eight patients with MB leprosy (7 LL and 1 BL), finding both rapid killing of M. leprae and clinical improvement, without serious side effects or toxicities. Here we report the outcomes in two patients treated with moxifloxacin. DESIGN: Two previously untreated LL patients were treated with a single 400 mg dose of moxifloxacin, no therapy for 7 days and then daily 400 mg moxifloxacin for 48 days. Clinical response, viability of M. leprae in the skin, and side effects/toxicities were carefully monitored. RESULTS: In both patients a single dose of moxifloxacin resulted in significant killing of M. leprae (P < 0.001%). In both patients no viable M. leprae were found after 15 doses of moxifloxacin. Improvement in skin lesions occurred again remarkably rapidly and no untoward effects were noted. CONCLUSION: Loss of viable M. leprae was quite rapid, similar to that found previously only for rifampicin, patients improved rapidly, and moxifloxacin was well tolerated.
Subject(s)
Aza Compounds/therapeutic use , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/drug therapy , Microbial Viability/drug effects , Mycobacterium leprae/drug effects , Quinolines/therapeutic use , Adult , Aza Compounds/administration & dosage , Fluoroquinolones , Humans , Leprostatic Agents/administration & dosage , Leprosy, Lepromatous/microbiology , Male , Middle Aged , Moxifloxacin , Mycobacterium leprae/isolation & purification , Quinolines/administration & dosage , Skin/microbiology , Skin/pathology , Treatment OutcomeABSTRACT
The diarylquinoline R207910 is profoundly bactericidal in a murine model of tuberculosis. Previously, R207910 was also found to be bactericidal for Mycobacterium leprae-infected mice during lag phase. Herein we evaluate the bactericidal efficacy of R207910 (1 to 120 mg/kg of body weight) when administered five times weekly, once weekly, and once monthly during logarithmic multiplication of M. leprae organisms. All treatments were found to be bactericidal, suggesting that both low and intermittent dosing with R207910 holds promise for leprosy patients.
Subject(s)
Antitubercular Agents/pharmacology , Quinolines/pharmacology , Animals , Antitubercular Agents/administration & dosage , Diarylquinolines , Drug Administration Schedule , Leprosy , Mice , Mycobacterium leprae/drug effects , Mycobacterium tuberculosis/drug effects , Quinolines/administration & dosageABSTRACT
In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P Subject(s)
Anti-Bacterial Agents/therapeutic use
, Aza Compounds/therapeutic use
, Leprosy/drug therapy
, Mycobacterium leprae/drug effects
, Quinolines/therapeutic use
, Adult
, Animals
, Anti-Bacterial Agents/administration & dosage
, Anti-Bacterial Agents/pharmacology
, Aza Compounds/administration & dosage
, Aza Compounds/pharmacology
, Fluoroquinolones
, Foot/microbiology
, Humans
, Leprosy/microbiology
, Leprosy/pathology
, Male
, Mice
, Middle Aged
, Moxifloxacin
, Mycobacterium leprae/growth & development
, Mycobacterium leprae/pathogenicity
, Quinolines/administration & dosage
, Quinolines/pharmacology
, Skin/microbiology
, Skin/pathology
, Treatment Outcome
